RxDoctor Payments Data

Anthony Dolomisiewicz, MD

Rheumatology · Rogers, ARNPI 1023515129

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Amgen at 34.4% of the total. That places this record below the midpoint for rheumatology clinicians in AR, where the typical reported total is $4,419.

$802in general payments, 2019–2025

Across 44 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$276
  • AbbVie$188
  • E.r. Squibb & Sons, L.L.C.$134
  • Pfizer$132
  • GSK$33
  • UCB, Inc.$21
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen16$276
AbbVie10$188
E.r. Squibb & Sons, L.L.C.6$134
Pfizer8$132
GSK2$33
UCB, Inc.1$21
AstraZeneca1$18

How this compares

$802 in reported general payments places this provider in the 30th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$160,269
Medicare patients
174
Services billed
5,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$79,948
BenlystaBelimumab13$73,277
Orencia ClickjectAbatacept11$61,395
Hydroxychloroquine Sulfate345$11,297
MethotrexateMethotrexate Sodium343$7,395
Leflunomide99$3,795
Mycophenolate Mofetil18$2,576
Azathioprine56$1,986
Colchicine31$1,910
Prednisone235$1,570
Naproxen61$652
Celecoxib16$598
Sulfasalazine28$576
Folic Acid45$481
Methotrexate SodiumMethotrexate Sodium/Pf31$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$33$73,27713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →